Russia's Sputnik V to be cheaper than other vaccines
Russian vaccine Sputnik V is likely to be cheaper than other candidates. Moreover, India will get priority when it comes to the Russian vaccine, Kirill Dmitriev, CEO of Russian Direct Investment Fund, has said. The first interim trial data analysis of Sputnik V against Covid-19 has shown that it is 92 per cent effective. Dmitriev, however, said if Indian regulators take time to clear the vaccine, it will be sent to other countries.
On nations hoarding vaccine stocks to meet their requirements first, Dmitriev said it is not about vaccine nationalism and that India is an important partner. He said manufacturers of its Covid-19 vaccine have been identified in India, the announcement regarding which will be made soon.
Dmitriev said the company is currently finalising the cost of the coronavirus vaccine and assured that it will be lower than many other vaccines. RDIF is backing the Russian COVID-19 vaccine and marketing it globally.
Sputnik V coronavirus vaccine is currently undergoing phase III testing stage in Belarus, UAE, Venezuela and other countries, while it is in phase II-III in India. The interim trial results regarding Sputnik V's efficacy were announced by RDIF on Wednesday. There were no untoward adverse events during the trials, it said, adding that monitoring of the participants is still going on. Interim results are based on data from the first 16,000 trial participants to receive both shots of the two-dose vaccine, the RDIF said.